Dalbavancin in the treatment of patients with Gram-positive diabetic foot infection: a case report

Dalbavancin is a potent lipoglycopeptide active against Gram+ bacteria with a favorable pharmacokinetic/pharmacodynamic (PK/PD) and safe­ty profile, suitable for numerous challenging infections. Dalbavancin has been approved for ABSSSIs, but its range of application and the relative posology is still debated. Diabetic foot infections are a major challenge and a leading source of complications, involving high direct and indirect costs for healthcare systems and for patients in terms of morbidity and disability. Gram+ bacteria are often causative agents in diabetic foot infections. We discuss here the case of a 43 yars old patient with complicated diabetic foot infection and the successful application of a dalbavancin secondary monotherapy treatment protocol. The patient, after suffering a two months complex hospitalisation gained wound haeling and limb rescue without any complication. We were also able to measures dalbavancin plasma lev­els determining its long half-life and high microbial killing ability. KEY WORDS dalbavancin, diabetic foot, gram-positive.